e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases

被引：17

作者：

Mondal, B. C.

Majumdar, S.

Dasgupta, U. B.

Chaudhuri, U.

Chakrabarti, P.

Bhattacharyya, S.

机构：

[1] Univ Calcutta, Dept Biophys Mol Biol & Genet, Kolkata 700009, W Bengal, India

[2] Inst Haematol & Transfus Med, Kolkata, W Bengal, India

来源：

JOURNAL OF CLINICAL PATHOLOGY | 2006年 / 59卷 / 10期

关键词：

D O I：

10.1136/jcp.2005.029595

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

This report describes two patients with chronic myeloid leukaemia (CML): one of them developed accelerated phase CML and died 8 years after diagnosis and the other is at the chronic phase. Sequence analysis of reverse transcription-polymerase chain reaction products showed the presence of BCR-ABL fusion transcript e19a2. This finding suggests that CML carrying mu-BCR breakpoint may exhibit a clinical course similar to typical CML.

引用

页码：1102 / 1103

页数：2

共 50 条

[41] Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up
Gendron, Nicolas
Belhouachi, Nabila
Morel, Veronique
Azgui, Zahia
Maloum, Karim
Florence Nguyen-Khac
Cayuela, Jean-Michel
Davi, Frederic
Merle-Beral, Helene
Chapiro, Elise
ANNALES DE BIOLOGIE CLINIQUE, 2014, 72 (03) : 359 - 366
[42] Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?
Stephen E. Langabeer
Medical Oncology, 2013, 30
[43] Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?
Langabeer, Stephen E.
MEDICAL ONCOLOGY, 2013, 30 (02)
[44] Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance
Verma, D.
Kantarjian, H.
Jones, D.
Borthakur, G.
Garcia-Manero, G.
Thomas, D. A.
Verstovsek, S.
Rios, M.
Cortes, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[45] A novel BCR-ABL fusion transcript (e15a2) in 2 patients with atypical chronic myeloproliferative syndrome
Moreno, MD
Cortinas, MN
Bonomi, R
Cardeza, A
Uriarte, MD
BLOOD, 2001, 97 (11) : 3668 - 3669
[46] Response to Imatinib Treatment in Chronic Myeloid Leukemia According to BCR-ABL Transcript
Acosta Hernandez, Titania del Carmen
Best Aguilera, Carlos Roberto
Villela Martinez, Luis Mario
Guzman Hernandez, Alicia Elizabeth
Robles Rodriguez, Arianna
Lopez Hernandez, Juan Carlos
Gomez Vazquez, Oscar Rodrigo
Rivera Mendoza, Laura Adriana
Garcia Reyes, Barbara
Gutierrez Alatorre, Aldo Fernando Adrian
Calderon Valdez, Areli Sarai
Visuetti Pimentel, Saribethe Mahely
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S242 - S243
[47] Chronic Myeloid Leukemia: Clinical Prestantation According to Bcr-Abl Transcript Variants
Acosta Hernandez, Titania del Carmen
Best Aguilera, Carlos Roberto
Villela Martinez, Luis Mario
Guzman Hernandez, Alicia Elizabeth
Robles Rodriguez, Arianna
Lopez Hernandez, Juan Carlos
Gomez Vazquez, Oscar Rodrigo
Rivera Mendoza, Laura Adriana
Garcia Reyes, Barbara
Gutierrez Alatorre, Aldo Fernando Adrian
Calderon Valdez, Areli Sarai
Visuetti Pimentel, Saribethe Mahely
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S243 - S243
[48] b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia
Norbury, LC
Clark, RE
Christmas, SE
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) : 616 - 621
[49] Identification of e19a2 BCR-ABL fusions (μ-BCR breakpoints) at the DNA level by ligation-mediated PCR
Boeckx, N
Jansen, MWJC
Vandenberghe, P
van der Velden, VHJ
van Dongen, JJM
LEUKEMIA, 2005, 19 (07) : 1292 - 1295
[50] Effect of BCR-ABL inhibition on induction of autophagy in chronic myeloid leukaemia cells
Mackay, C. E.
Allen, E. K.
Mukhopadhyay, A.
Karvela, M.
Holyoake, T. L.
Jorgensen, H. G.
Helgason, G. V.
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 58 - 58

← 1 2 3 4 5 →